Haemophilia in the developing countries: The Iranian experience

Archives of Medical Science

Volumn 6, Issue 1, 2010, Pages 83-89

  Eshghi, Peyman ^a   Mahdavi Mazdeh, Mitra ^b   Karimi, Mehran ^c   Aghighi, Mohammad ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Developing world; Haemophilia Care; Iran

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DESMOPRESSIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; BLOODSTREAM INFECTION; DEVELOPING COUNTRY; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH STATUS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IRAN; MAJOR CLINICAL STUDY; MORBIDITY; PATIENT CARE; PRENATAL DIAGNOSIS; PREVALENCE; QUALITY OF LIFE; VON WILLEBRAND DISEASE;

EID: 77949408196     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.13512     Document Type: Article

References (50)

1. Giangrande PL. Blood products for hemophilia: past, present and future. BioDrugs 2004; 18: 225-34.
2. Chuansumrit A. Treatment of haemophilia in the developing countries. Haemophilia 2003; 9: 387-90.
3. Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost 2003; 1: 1349-55.
4. Mathews V, Viswabandya A, Baidya S, et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 538-43.
5. Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol 2006; 132: 671-82.
6. Smith PS, Levine PH. The benefits of comprehensive care of hemophilia: a five-year study of outcomes. Am J Public Health 1984; 74: 616-7.
7. Jones P. Hemophilia home therapy. Homeostasis 1992; 22: 247-50.
8. World Federation of Haemophilia. Annual Report 200. Montreal, Canada: WFH, 2001.
9. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1988; 4: 474-80.
10. Srivastava A, You SK, Ayob Y, et al. Hemophilia treatment in developing countries: products and protocols. Semin Thromb Hemost 2005; 31: 495-500.
11. Ghosh K. Management of haemophilia and its complications in developing countries. Clin Lab Haematol 2004; 26: 243-51.
12. Antunes SV. Haemophilia in the developing world: the Brazilian experience. Haemophilia 2002; 8: 199-204.
13. World factbook/Iran:www.CIA.org.
14. IMF GDP per capita ranking: www.imf.org.
15. Giangrande PL, Black C. World Federation of Haemophilia programs in developing countries. Semin Thromb Hemost 2005; 31: 555-60.
16. Available at: www.hemophilia.org.ir.
17. Bghaiepour A. Hemophilia in IRAN. Regional Hemophilia Seminar, April 2004, Mahmood Abad, Iran.
18. Tchupan A. Developing a national patient registry Iranian experience. International meeting on challenges on Hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.
19. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004; 77: 198-9.
20. Lak M, Peyvandi F, Mannucci P. Clinical manifestations and complications of child birth and replacement therapy in 385 Iranian patients with type 3 Von Wilbrand disease. Br J Haematol 2000; 111: 1236-9.
21. World Federation of Haemophilia. Report on the WFH Global Survey 2001. Montreal, Canada: WFH, 2001.
22. Tizzano EF, Altisent C, Domenech M, Cornet M, Tusell J, Baiget M. Inhibitor development in hemophilia A patients with inversion of the intron 22 of the factor VIII gene. Thromb Haemost 1996; 76: 125-6.
23. Vermylen J. How do some hemophiliacs develop inhibitor? Haemoplilia 1998; 4: 538-42.
24. Ghosh K, Shetty S, Kulkarni B, et al. Development of inhibitors in patients with haemophilia from India. Haemophilia 2001; 7: 273-8.
25. Kavakli K, Gringeri A, Bader R, Nisli G, Polat A, Aydinok Y. Inhibitor developments and substitution therapy in a developing country: Turkey. Haemophilia 1998; 4: 104-8.
26. Sharifian R, Hosseini M. Prevalence of inhibitor in 1280 cases with Hemophilia. Acta Medica Iranica 2003; 41: 66-8.
27. Eshghi P, Jazebi M, Hoorfar H, et al. Multicentric screening of factor VIII inhibitor in 355 Hemophilia a patients in IRAN 2005. Haemophilia 2006; 12: 60.
28. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iran Med 2005; 8: 84-90.
29. Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, Southeast Iran. Saudi Med J 2007; 28: 1516.
30. Alavian SM, Ardeshiri A, Hajarizadeh B. Prevalence of HCV, HIV and HBS-Ag among Hemophiliac patients. Hakim Research J 2003; 6: 45-51.
31. Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap) 2001; 31: 251-5.
32. Mansour-Ghanaei F, Fallah MS, Shafaghi A, Yousefi-Mashhoor M, et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). East Mediterr Health J 2005; 11: 372.
33. Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica 2003; 13: 124-8.
34. Chakrabarti S, Pradhan P, Roy A, Hira M, Bandyopadhyay G, Bhattacharya DK. Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products. Indian J Public Health 2006; 50: 43-4.
35. Federici AB, Santagostino E, Rumi MG, et al. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. Haematologica 2006; 91: 503-8.
36. Silva LK, Silva MB, Lopes GB, et al. Prevalence of hepatitis C virus infection and HCV genotypes among hemophiliacs in the State of Bahia, Northeastern Brazil: analysis of serological and virological parameters. Rev Soc Bras Med Trop 2005; 38: 496-502.
37. Al-Kubaisy WA, Al-Naib KT, Habib MA. Prevalence of HCV/HIV co-infection among Haemophilia patients in Baghdad. East Mediterr Health J 2006; 12: 264-9.
38. Alavian SM. Control of hepatitis C in Iran: vision and missions. Hepatitis 2007; 7: 57-8.
39. Houri R, Taroyan S, Jalali S, Keyhani M. A study on Hiv-1 infection amongst Hemophiliacs in Iran. Int Conf Aids 1989; 5: 1007 (Abstract No. T.G.P.20).
40. Hoorfar H, MobarakyG. Quality of life in severe hemophilia in Esfahan. Haemophilia 2006; 12: 122.
41. Mortazavi SM, Asadollahi S, Farzan M, et al. (32)P Colloid radiosynovectomy in treatment of chronic haemophilic synovitis: Iran experience. Haemophilia 2007; 13: 182-8.
42. Cheraghali AM. Availability of blood components and plasma derived medicines in Iran. Transf Apheres Sci 2007, 37: 3-7.
43. Cheragh-ali A. Plasma fractionation in Iran, international meeting on challenges on hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.
44. Chandy M. Treatment Options in the Management of Hemophilia in Developing Countries. Treatment of Hemophilia. December 2005, Number 37.
45. Kasper CK. Products for clotting factor replacement in developing countries: seminars in Thrombosis & Hemostasis. Hemophilia and von Willebrand Disease in Developing Countries. 2005; 31: 507-12.
46. Karimi M. Health status and costs of care in Iranian hemophilic patients, International meeting on challenges on hemophilia treatment in developing countries. Feb. 5-7 2006, Tehran, Iran.
47. Globe DR, Cunningham WE, Andersen RM, et al. The Haemophilia Utilization Group Study (Hugs): determinants of costs of care in persons with haemophilia. Haemophilia 2003; 9: 325-31.
48. Schramm W, Royal S, Kroner B, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
49. Rastegar Lari G, Enayat MS, Arjang Z, Lavergne JM, Ala F. Identification of Intron 1 and 22 inversion mutations in the factor Viii gene of 124 Iranian families with severe haemophilia A. Haemophilia 2004; 10: 410-1.
50. Karimi M, Peyvandi F, Siboni S, Ardeshiri R, Gringeri A, Mannucci PM. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy of haemophilia in Iran and Italy. Haemophilia 2004; 10: 367-9.